Celldex Therapeutics News Releases https://ir.celldex.com/ Celldex Therapeutics News Releases en Celldex Provides Corporate Update and Reports First Quarter 2019 Results https://ir.celldex.com/news-releases/news-release-details/celldex-provides-corporate-update-and-reports-first-quarter-2019 HAMPTON, N.J. , May 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019 . “Celldex presented positive data across multiple programs at AACR in April, including from our promising CDX-1140 Tue, 07 May 2019 16:01:00 -0400 Celldex Therapeutics News Releases 13011 Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019 https://ir.celldex.com/news-releases/news-release-details/celldex-presents-positive-interim-results-phase-1-study-cd40 --CDX-1140 has achieved good systemic exposure without reaching a maximum tolerated dose to date-- --Addition of dendritic cell growth factor CDX-301 enhances cytokine response without additive toxicity at dose levels tested to date-- --Tumor specific expansion cohorts planned-- HAMPTON, N.J. Tue, 02 Apr 2019 08:00:00 -0400 Celldex Therapeutics News Releases 12996 Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019 https://ir.celldex.com/news-releases/news-release-details/celldex-presents-promising-data-cdx-527-bispecific-and-tam HAMPTON, N.J. , April 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AACR) Annual Meeting Mon, 01 Apr 2019 13:00:00 -0400 Celldex Therapeutics News Releases 12991 Celldex Provides Corporate Update and Reports Full Year 2018 Results https://ir.celldex.com/news-releases/news-release-details/celldex-provides-corporate-update-and-reports-full-year-2018 HAMPTON, N.J. , March 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2018 . The Company will host a conference call at 4:30 p.m. Thu, 07 Mar 2019 16:01:00 -0500 Celldex Therapeutics News Releases 12976 Celldex to Report Full Year 2018 Business/Financial Results and Host Corporate Update Call https://ir.celldex.com/news-releases/news-release-details/celldex-report-full-year-2018-businessfinancial-results-and-host HAMPTON, N.J. , March 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2018 financial results on Thursday, March 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. Fri, 01 Mar 2019 08:01:00 -0500 Celldex Therapeutics News Releases 12966 Celldex Therapeutics Announces Reverse Stock Split https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-announces-reverse-stock-split HAMPTON, N.J. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary Fri, 08 Feb 2019 11:45:00 -0500 Celldex Therapeutics News Releases 12941 Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting https://ir.celldex.com/news-releases/news-release-details/celldex-presents-emerging-mertk-antibody-program-society Antibody technology provides an exciting new approach to enhance innate immune function in cancer HAMPTON, N.J. , Nov. 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company’s MerTK antibody program in a poster session today at the Society for Sat, 10 Nov 2018 08:01:00 -0500 Celldex Therapeutics News Releases 12921 Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting https://ir.celldex.com/news-releases/news-release-details/celldex-presents-promising-interim-data-phase-1-study --Well tolerated; dose dependent biological effects consistent with CD40-mediated immune cell activity-- --Program development expanded based on results observed to date-- HAMPTON, N.J. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented interim data today from Fri, 09 Nov 2018 08:01:00 -0500 Celldex Therapeutics News Releases 12916 Celldex Provides Corporate Update and Reports Third Quarter 2018 Results https://ir.celldex.com/news-releases/news-release-details/celldex-provides-corporate-update-and-reports-third-quarter-2018 HAMPTON, N.J. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2018 . “We made considerable progress in the third quarter, particularly in the development program for CDX-1140, our Wed, 07 Nov 2018 16:01:00 -0500 Celldex Therapeutics News Releases 12896 Celldex Provides Corporate Update and Reports Second Quarter 2018 Results https://ir.celldex.com/news-releases/news-release-details/celldex-provides-corporate-update-and-reports-second-quarter HAMPTON, N.J. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2018 . The Company will host a conference call at 4:30 p.m. ET today to provide an in-depth update on its pipeline and Wed, 08 Aug 2018 16:01:00 -0400 Celldex Therapeutics News Releases 12856